Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Among patients with asthma who received four doses of depemokimab over 2 years, the annualized exacerbation rate was low, ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

Artificial intelligence (AI) and natural language processing tools can build an algorithm that identifies patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbations, ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Depemokimab significantly reduces asthma exacerbations, showing similar efficacy in both controlled and uncontrolled asthma patients. The study included patients with eosinophilic asthma using medium- ...

Panelists discuss how reducing bronchiectasis exacerbations requires standardized definitions, tailored antibiotic approaches, and increased airway clearance, while addressing underlying conditions ...